Search: WFRF:(Sayin Volkan I. 1983) >
Assessing the progn...
-
Eklund, Ella AGothenburg University,Göteborgs universitet,Wallenberg Centre for Molecular and Translational Medicine,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
(author)
Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis
- Article/chapterEnglish2024
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/339390
-
https://gup.ub.gu.se/publication/339390URI
-
https://doi.org/10.3389/fonc.2024.1396285DOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: KRAS mutation status is a well-established independent prognostic factor in advanced non-small cell lung cancer (NSCLC), yet its role in early-stage disease is unclear. Here, we investigate the prognostic value of combining survival data on KRAS mutation status and tumor size in stage I-II NSCLC. Methods: We studied the combined impact of KRAS mutational status and tumor size on overall survival (OS) in patients with stage I-II NSCLC. We performed a retrospective study including 310 diagnosed patients with early (stage I-II) NSCLCs. All molecularly assessed patients diagnosed with stage I-II NSCLC between 2016-2018 in the V & auml;stra G & ouml;taland Region of western Sweden were screened in this multi-center retrospective study. The primary study outcome was overall survival. Results: Out of 310 patients with stage I-II NSCLC, 37% harbored an activating mutation in the KRAS gene. Our study confirmed staging and tumor size as prognostic factors. However, KRAS mutational status was not found to impact OS and there was no difference in the risk of death when combining KRAS mutational status and primary tumor size. Conclusions: In our patient cohort, KRAS mutations in combination with primary tumor size did not impact prognosis in stage I-II NSCLC.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Mourad, Ali,1996Gothenburg University,Göteborgs universitet,Wallenberg Centre for Molecular and Translational Medicine,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery(Swepub:gu)xmoura
(author)
-
Wiel, Clotilde,1987Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery(Swepub:gu)xwiecl
(author)
-
Sayin, Sama I.
(author)
-
Fagman, Henrik,1975Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine(Swepub:gu)xfagmh
(author)
-
Hallqvist, Andreas,1973Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xhands
(author)
-
Sayin, Volkan I.,1983Gothenburg University,Göteborgs universitet,Wallenberg Centre for Molecular and Translational Medicine,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery(Swepub:gu)xsayvo
(author)
-
Göteborgs universitetWallenberg Centre for Molecular and Translational Medicine
(creator_code:org_t)
Related titles
-
In:FRONTIERS IN ONCOLOGY142234-943X
Internet link
Find in a library
To the university's database
- By the author/editor
-
Eklund, Ella A
-
Mourad, Ali, 199 ...
-
Wiel, Clotilde, ...
-
Sayin, Sama I.
-
Fagman, Henrik, ...
-
Hallqvist, Andre ...
-
show more...
-
Sayin, Volkan I. ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
- Articles in the publication
-
FRONTIERS IN ONC ...
- By the university
-
University of Gothenburg